DNA-directed DNAP inhibitor

DRUG CLASS:

DNA-directed DNAP inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	cytarabine + methotrexate Sensitive: A2 - Guideline cytarabine + methotrexate Sensitive : A2	cytarabine + methotrexate Sensitive: A2 - Guideline cytarabine + methotrexate Sensitive : A2
No biomarker	Lymphoma	No biomarker	Lymphoma	cytarabine Sensitive: A2 - Guideline cytarabine Sensitive : A2	cytarabine Sensitive: A2 - Guideline cytarabine Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	cytarabine + methotrexate + idarubicin Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin Sensitive : A2	cytarabine + methotrexate + idarubicin Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine Sensitive: A2 - Guideline cytarabine Sensitive : A2	cytarabine Sensitive: A2 - Guideline cytarabine Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + fludarabine IV + GCSF Sensitive: A2 - Guideline cytarabine + fludarabine IV + GCSF Sensitive : A2	cytarabine + fludarabine IV + GCSF Sensitive: A2 - Guideline cytarabine + fludarabine IV + GCSF Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive : A2	cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF Sensitive : A2
No biomarker	Acute Promyelocytic Leukemia	No biomarker	Acute Promyelocytic Leukemia	cytarabine + daunorubicin Sensitive: A2 - Guideline cytarabine + daunorubicin Sensitive : A2	cytarabine + daunorubicin Sensitive: A2 - Guideline cytarabine + daunorubicin Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + daunorubicin Sensitive: A2 - Guideline cytarabine + daunorubicin Sensitive : A2	cytarabine + daunorubicin Sensitive: A2 - Guideline cytarabine + daunorubicin Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride Sensitive : A2	cytarabine + idarubicin hydrochloride Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + etoposide IV + mitoxantrone Sensitive: A2 - Guideline cytarabine + etoposide IV + mitoxantrone Sensitive : A2	cytarabine + etoposide IV + mitoxantrone Sensitive: A2 - Guideline cytarabine + etoposide IV + mitoxantrone Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + etoposide IV Sensitive: A2 - Guideline cytarabine + etoposide IV Sensitive : A2	cytarabine + etoposide IV Sensitive: A2 - Guideline cytarabine + etoposide IV Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + cladribine + Nugraf (filgrastim biosimilar) Sensitive: A2 - Guideline cytarabine + cladribine + Nugraf (filgrastim biosimilar) Sensitive : A2	cytarabine + cladribine + Nugraf (filgrastim biosimilar) Sensitive: A2 - Guideline cytarabine + cladribine + Nugraf (filgrastim biosimilar) Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + clofarabine Sensitive: A2 - Guideline cytarabine + clofarabine Sensitive : A2	cytarabine + clofarabine Sensitive: A2 - Guideline cytarabine + clofarabine Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar) Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar) Sensitive : A2	cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar) Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar) Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar) Sensitive: A2 - Guideline cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar) Sensitive : A2	cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar) Sensitive: A2 - Guideline cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar) Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	cytarabine + methotrexate + idarubicin hydrochloride Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin hydrochloride Sensitive : A2	cytarabine + methotrexate + idarubicin hydrochloride Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin hydrochloride Sensitive : A2
No biomarker	Lymphoma	No biomarker	Lymphoma	cytarabine + thiotepa Sensitive: A2 - Guideline cytarabine + thiotepa Sensitive : A2	cytarabine + thiotepa Sensitive: A2 - Guideline cytarabine + thiotepa Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	cytarabine + etoposide IV + mitoxantrone Sensitive: A2 - Guideline cytarabine + etoposide IV + mitoxantrone Sensitive : A2	cytarabine + etoposide IV + mitoxantrone Sensitive: A2 - Guideline cytarabine + etoposide IV + mitoxantrone Sensitive : A2
No biomarker	Lymphoma	No biomarker	Lymphoma	cytarabine + methotrexate + thiotepa Sensitive: A2 - Guideline cytarabine + methotrexate + thiotepa Sensitive : A2	cytarabine + methotrexate + thiotepa Sensitive: A2 - Guideline cytarabine + methotrexate + thiotepa Sensitive : A2
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2
No biomarker	T Cell Non-Hodgkin Lymphoma	No biomarker	T Cell Non-Hodgkin Lymphoma	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	cytarabine Resistant: B - Late Trials cytarabine Resistant : B	cytarabine Resistant: B - Late Trials cytarabine Resistant : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine Sensitive: B - Late Trials cytarabine Sensitive : B	cytarabine Sensitive: B - Late Trials cytarabine Sensitive : B
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	cytarabine Resistant: B - Late Trials cytarabine Resistant : B	cytarabine Resistant: B - Late Trials cytarabine Resistant : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride Sensitive: C2 – Inclusion Criteria cytarabine + idarubicin hydrochloride Sensitive : C2	cytarabine + idarubicin hydrochloride Sensitive: C2 – Inclusion Criteria cytarabine + idarubicin hydrochloride Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin Sensitive: C2 – Inclusion Criteria cytarabine + midostaurin Sensitive : C2	cytarabine + midostaurin Sensitive: C2 – Inclusion Criteria cytarabine + midostaurin Sensitive : C2
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3

DNA-directed DNAP inhibitor

DNA-directed DNAP inhibitor

Associations(99)

Associations
(99)